Current use of phosphodiesterase inhibitors in urology

HAKKY, Tarig Said; JAİN, Lakshay

Current use of phosphodiesterase inhibitors in urology

Tarig Said HAKKY, (Baylor College of Medicine, Houston, Texas, USA)

Lakshay JAİN (Baylor College of Medicine, Houston, Texas, USA)

Turkish Journal of Urology

0 0

Yıl: 2015 Cilt: 41 Sayı: 2 Sayfa Aralığı: 88 - 92 Metin Dili: Türkçe İndeks Tarihi: 29-07-2022

Current use of phosphodiesterase inhibitors in urology

Öz:

Erkekte erektil disfonksiyon (ED) nedenleri oldukça değişkendir ve artık yaygın olarak, iskemi, yumuşakkas hasarı veya değişmiş kan akımı gibi etiyolojilere ayrılmaktadır. Literatürde değişen ED sıklıkları bil- dirilmiş olmasına rağmen, dünyada ED olan erkeklerin sayısının 2025 yılı itibariyle yaklaşık 322 milyonaartması beklenmektedir. Fosfodiesteraz 5 (PDE5) inhibitörlerinin kullanıma girmesinden bu yana ED te- davisinde bir bilgi değişimi olmuştur, çünkü PDE5 inhibitörleri geniş bir etiyolojik yelpazede EDye hitapetmektedir. Bugün, Amerikan Üroloji Birliği ED tedavisi için ilk basamak tedavi olarak üç PDE5 inhibitö- rünün (sildenafil, tadalafil ve vardenafil) kullanılmasını önermektedir. Bu derlemede sildenafil, vardenafil,tadalafil ve avanafilin kullanımı ve etkisi ile birlikte PDE5 inhibitörlerinin farmakolojik mekanizmasıdeğerlendirilmektedir. PDE5 inhibitörlerinin ED tedavisinde hücre içi cGMP düzeylerini artırarak etkiliolduğu gösterilmiştir. Diğer hücre sinyal yolakları üzerindeki etkileri sayesinde, PDE5 inhibitörleri diğerürolojik koşulların tedavi potansiyeline de sahiptir. PDE5 inhibitörlerinin kullanımı, aynı zamanda EDyeilave olarak, erkek hipogonadizmi ve benign prostat hiperplazisi gibi durumlarda sinerjistik bir etki eldeetmek için kombinasyonlarda kullanılabilir.

Anahtar Kelime:

Konular: Üroloji ve Nefroloji

Ürolojide fosfodiesteraz inhibitörlerinin güncel kullanımı

Öz:

The causes of male erectile dysfunction (ED) are quite variable and are now commonly divided into etiolo- gies such as ischemia, smooth muscle damage, or altered blood flow. Although varying rates of ED have beenreported in literature, the number of men with ED is projected to increase worldwide by 2025 to approximately322 million. Since the introduction of phosphodiesterase 5 (PDE5) inhibitors, there has been a paradigm shiftin the treatment of ED because PDE5 inhibitors address a broad spectrum of etiologies for ED. Today, theAmerican Urological Association recommends the use of three PDE5 inhibitors (sildenafil, tadalafil, and var- denafil) as a first-line therapy for the treatment of ED. This review evaluates the pharmacological mechanismof PDE5 inhibitors along with the impact and use of sildenafil, vardenafil, tadalafil, and avanafil. By increasingintracellular cGMP levels, PDE5 inhibitors have been shown to be effective in the treatment of ED. Throughtheir effects on other cellular signaling pathways, PDE5 inhibitors have the potential for treating other urologicconditions as well. The use of PDE5 inhibitors can also be combined to produce a synergistic effect in condi- tions such as male hypogonadism and benign prostatic hyperplasia in addition to ED.

Anahtar Kelime:

Konular: Üroloji ve Nefroloji

Belge Türü: Makale Makale Türü: Derleme Erişim Türü: Erişime Açık

1. Setter SM, Iltz JL, Fincham JE, Campbell RK, Baker DE. Phosphodiesterase 5 inhibitors for erectile dysfunction. Ann Pharmacother 2005;39:1286-95. [CrossRef]
2. Lue TF, Hon S. Pathophysiology of erectile dysfunction. Campbell- Walsh Urology 2000;688-70.
3. Houry SK, Harlip IS. Sexual medicine sexual dysfunction in men and women. 2010. p. 19-22.
4. Ayta IA, McKinlay JB, Krane RJ. The likely worldwide increase in erectile dysfunction between 1995 and 2025 and some possible policy consequences. BJU Int 1999;84:50-6. [CrossRef]
5. Crowe SM, Streetman DS. Vardenafil treatment for erectile dys- function. Ann Pharmacother 2004;38:77-85. [CrossRef]
6. Limin M, Johnsen N, Hellstrom WJ. Avanafil, a new rapid-onset phosphodiesterase 5 inhibitor for the treatment of erectile dysfunc- tion. Expert Opin Investig Drugs 2010;19:1427-37. [CrossRef]
7. Alwaal A, Al-Mannie R, Carrier S. Future prospects in the treatment of erectile dysfunction: focus on avanafil. Drug Des Devel Ther 2011;5:435-43.
8. Kuthe A. Phosphodiesterase 5 inhibitors in male sexual dysfunction. Curr Opin Urol 2003;13:405-10. [CrossRef]
9. Basu A, Ryder RE. New treatment options for erectile dysfunc- tion in patients with diabetes mellitus. Drugs 2004;64:2667-88. [CrossRef]
10. Goldstein I, Lue TF, Padma-Nathan H, Rosen RC, Steers WD, Wicker PA. Oral sildenafil in the treatment of erectile dysfunc- tion. Sildenafil Study Group. N Engl J Med 1998;338:1397-404. [CrossRef]
11. Saenz de Tejada I, Frutos JA, Gaudo M, Florio V. Comparative selectivity: profiles of tadalafil, sildenafil and vardenafil using an in vitro phosphodiesterase activity assay. Int J Impot Res 2002;14:20- 32.
12. Porst H. IC351 (tadalafil, Cialis): update on clinical experience. Int J Impot Re 2002;14:57-64. [CrossRef]
13. Hellstrom WJ, Gittelman M, Karlin G, Segerson T, Thibonnier M, Taylor T, et al. Vardenafil for treatment of men with erectile dysfunction: efficacy and safety in a randomized, double-blind, placebo-controlled trial. J Androl 2002;23:763-71.
14. Carson CC 3rd. Cardiac safety in clinical trials of phosphodiesterase 5 inhibitors. Am J Cardiol 2005;96:37-41. [CrossRef]
15. Eardley I, Cartledge J. Tadalafil (Cialis) for me with erectile dys- function. Int J Clin Pract 2002;56:300-4.
16. Brock GB. Tadalafil: a new agent for erectile dysfunction. Can J Urol 2003;10:17-22.
17. Briganti A, Salonia A, Deho F, Zanni G, Barbieri L, Rigatti P, et al. Clinical update on phosphodiesterase type-5 inhibitors for erectile dysfunction. World J Urol 2005;23:374-84. [CrossRef]
18. Brock GB, McMahon CG, Chen KK, Costigan T, Shen W, Watkins V, et al. Efficacy and safety of tadalafil for the treatment of erec- tile dysfunction: results of integrated analyses. J Urol 2002;168: 1332-6. [CrossRef]
19. Gacci M, Corona G, Salvi M, Vignozzi L, McVary KT, Kaplan SA, et al. A systematic review and meta-analysis on the use of phospho- diesterase 5 inhibitors alone or in combination with α-blockers for lower urinary tract symptoms due to benign prostatic hyperplasia. Eur Urol 2012;61:994-1003. [CrossRef]
20. Andersson KE, de Groat WC, McVary KT, Lue TF, Maggi M, Roehrborn CG, et al. Tadalafil for the treatment of lower uri- nary tract symptoms secondary to benign prostatic hyperplasia: pathophysiology and mechanism(s) of action. Neurourol Urodyn 2011;30:292-301. [CrossRef]
21. Kaplan SA. Tadalafil for the treatment of benign prostatic hyper- plasia: When the moment does not add up. Eur Urol 2013;63: 517-8. [CrossRef]
22. Kaplan S. Tadalafil for the treatment of benign prostatic hyperpla- sia: When the moment does not add up. Eur Urol 2012:11-12.
23. Clinical practice guidelines. Management of BPH. American Urological Association Web site 2010, revised. http://www.aua- net.org/content/clinical-practice-guidelines/clinical-guidelines. cfm?sub=bph.
24. Oelke M, Bachmann A, Descazeaud A, Emberton M, Gravas S, Michel MC, et al. EAU guidelines on the treatment and follow-up of non-neurogenic male lower urinary tract symptoms including benign prostatic obstruction. Eur Urol 2013;64:118-40. [CrossRef]
25. Mills TM, Stopper VS, Wiedmeier VT. Effects of castration and androgen replacement on the hemodynamics of penile erection in the rat. Biol Reprod 1994;51:234-8. [CrossRef]
26. Penson DF, Ng C, Rajfer J, Gonzalez-Cadavid NF. Adrenal con- trol of erectile function and nitric oxide synthase in the rat penis. Endocrinology 1997;138:3925-32. [CrossRef]
27. Alhathal N, Elshal AM, Carrier S. Synergetic effect of testosterone and phophodiesterase-5 inhibitors in hypogonadal men with erectile dysfunction: A systematic review. Can Urol Assoc J 2012;6:269-74. [CrossRef]
28. Dimitriadis F, Tsambalas S, Tsounapi P, Kawamura H, Vlachopoulou E, Haliasos N, et al. Effects of phosphodiesterase-5 inhibitors on Leydig cell secretory function in oligoasthenospermic infertile men: a randomized trial. BJU Int 2010;106:1181-5. [CrossRef]

APA	HAKKY T, JAİN L (2015). Current use of phosphodiesterase inhibitors in urology. , 88 - 92.
Chicago	HAKKY Tarig Said,JAİN Lakshay Current use of phosphodiesterase inhibitors in urology. (2015): 88 - 92.
MLA	HAKKY Tarig Said,JAİN Lakshay Current use of phosphodiesterase inhibitors in urology. , 2015, ss.88 - 92.
AMA	HAKKY T,JAİN L Current use of phosphodiesterase inhibitors in urology. . 2015; 88 - 92.
Vancouver	HAKKY T,JAİN L Current use of phosphodiesterase inhibitors in urology. . 2015; 88 - 92.
IEEE	HAKKY T,JAİN L "Current use of phosphodiesterase inhibitors in urology." , ss.88 - 92, 2015.
ISNAD	HAKKY, Tarig Said - JAİN, Lakshay. "Current use of phosphodiesterase inhibitors in urology". (2015), 88-92.

APA	HAKKY T, JAİN L (2015). Current use of phosphodiesterase inhibitors in urology. Turkish Journal of Urology, 41(2), 88 - 92.
Chicago	HAKKY Tarig Said,JAİN Lakshay Current use of phosphodiesterase inhibitors in urology. Turkish Journal of Urology 41, no.2 (2015): 88 - 92.
MLA	HAKKY Tarig Said,JAİN Lakshay Current use of phosphodiesterase inhibitors in urology. Turkish Journal of Urology, vol.41, no.2, 2015, ss.88 - 92.
AMA	HAKKY T,JAİN L Current use of phosphodiesterase inhibitors in urology. Turkish Journal of Urology. 2015; 41(2): 88 - 92.
Vancouver	HAKKY T,JAİN L Current use of phosphodiesterase inhibitors in urology. Turkish Journal of Urology. 2015; 41(2): 88 - 92.
IEEE	HAKKY T,JAİN L "Current use of phosphodiesterase inhibitors in urology." Turkish Journal of Urology, 41, ss.88 - 92, 2015.
ISNAD	HAKKY, Tarig Said - JAİN, Lakshay. "Current use of phosphodiesterase inhibitors in urology". Turkish Journal of Urology 41/2 (2015), 88-92.